HDMBLM logo en

Plenary lecturers

Anamarija Simundic

Prof. Ana-Maria Šimundić,
PhD, Specialist in laboratory medicine

Director of Department of Medical Laboratory Diagnostics,
University Hospital „Sveti Duh“, Croatia

 
 

Prof. Šimundić graduated from the Faculty of Pharmacy and Biochemistry, University of Zagreb in 1994, where she received her Master of Science degree in 2000, and PhD degree in 2003. In 2004 she received Master degree in Healthcare Management at Zagreb University School of Medicine and in 2005 passed the final examination after vocational training in Laboratory Medicine. During 1997 she attended training at University of Connecticut Health Center in Farmington, USA. She was promoted to Assistant Professor in 2008 and to Associate Professor in 2013 at the Faculty of Pharmacy and Biochemistry, University of Zagreb.

Prof. Šimundić was employed at Clinical Institute of Chemistry, University Hospital Center “Sestre milosrdnice” between 1995 and 2015, where she was Head of the Department of Clinical Chemistry and Analytical Toxicology, Department of Molecular Diagnostics and Department for Sample Management and Distribution. Since 2015 prof. Šimundić has been employed as the Director of the Department of Medical Laboratory Diagnostics, University Hospital „Sveti Duh“.

Prof. Šimundić is involved as a lecturer or study program coordinator in graduate, post-graduate and doctoral studies at the Faculty of Pharmacy and Biochemistry, University of Zagreb, Dubrovnik International University (DIU) post-graduate study Quality Management in Healthcare, and as visiting lecturer in Doctoral study at Faculty of Pharmacy in Tuzla. From 2009 to 2014 prof. Šimundić was scientific director of the project granted by Ministry of Science, Education and Sports: “Inflammation and pharmacogenetics modulation in acute and chronic diseases“. She was mentor to many candidates for graduate and master theses as well as for doctoral dissertations.

In 2012 prof. Šimundić was elected President of Croatian Society for Medical Biochemistry and Laboratory Medicine and she will fulfill her duties until the end of her mandate in 2018. In scientific journal Biochemia Medica prof. Šimundić was Assistant Editor from 2006 to 2011, while from 2011 to 2017 she was Editor-in-chief. She withdrew from that position in November of 2017. At present she is engaged in Biochemia Medica as Senior Editor.

Prof. Šimundić has been involved in more than 70 national and international scientific and professional events as an organizer, director or as invited speaker. She has published numerous book and textbook chapters. She has also published more than 120 scientific and professional articles on various topics (stroke, molecular diagnostics, biostatistics, quality management, preanalytical phase, and accreditation) in national and international journals.

From 2011 to 2017 prof. Šimundić was Secretary and member of Executive Board of European Federation of Clinical Chemistry and Laboratory Medicine (EFLM). EFLM general assembly elected her vice-president in mandate 2018-2019. After that, according to the EFLM-statute, she will be appointed president in mandate 2020-2021 Except for aforementioned duties in EFLM, prof. Šimundić is also actively engaged as Chair of the Working Group for Preanalytical Phase (WG-PRE) since 2011 until today. As a chair of WG PRE she started many projects aiming at standardization of preanalytical phase in Europe, published numerous recommendations and survey results, introduced award for the best study in preanalytical phase (Walter Guder Preanalytical award) and chaired Organizing and Scientific Committees of 5 consecutive conferences on preanalytical phase (EFLM European Conference on Preanalytical Phase) held in Parma (2011), Zagreb (2013), Porto (2015) and Amsterdam (2017), and fifth which will be held in Zagreb in 2019.

Prof. Šimundić has received numerous acknowledgments and awards:
2000 Annual award for most successful Young Scientist (Croatian Society for Medical Biochemistry and Laboratory Medicine-CSMBLM);
2002 IFCC-Roche Diagnostics Award;
2011 Annual Award for Scientific Work (CSMBLM);
2012 appointed honorary member of Hungarian Society for Laboratory Medicine; she was awarded Per Hyltoft Petersen Award for international activities in 2012;
2015 She was included in the list of 100 most important scientists in 2015 – The Powerlist of the journal The Pathologist, according to readers’ selection.


Gilbert Wieringa

 

Dr. Gilbert Wieringa

Consultant and Clinical Lead for Laboratory Medicine, Laboratory Medicine Bolton NHS Foundation Trust, Farnworth - United Kingdom

 

 

Following graduation from London University with a first degree in Biochemistry, Gilbert took his MSc in Clinical Biochemistry in Leeds in 1983 and went on to take FRCPath, the UK recognised exit qualification for specialists in laboratory medicine in 1994. He has benefited from the diverse opportunities offered to specialist roles that have included:

  • Establishing on-site blood sciences services at the Christie Hospital in Manchester (1998) where he has also conducted clinical research into the metabolic effects of growth hormone on lipid metabolism culminating in an international initiative in 2003 amongst clinicians, scientists, journals and the diagnostic industry to reduce variability in growth hormone measurements by standardising measurement on one calibrant (IS 98/574) and one reporting unit (mg/L).
  • National meetings secretary for the Association of Clinical Biochemists (2003-2006), chair Focus 2003, and chair UEMS/EFLM 2014 Conference (Laboratory Medicine at the Clinical Interface) in Liverpool, UK
  • Over 2004/2005 he was the diagnostics lead for Greater Manchester Strategic Health Authority leading the implementation of General Practitioner’s (GP) direct access to community-based mobile MRI scanning facilities, diagnostic testing in emergency ambulances, and the provision of point of care testing in ‘high street’ pharmacies across Manchester for GP-referred patients with diabetes and/or heart disease. The latter work won the Department of Health’s Chief Scientific Officer’s award for innovation in 2007, the Health and Social Care ‘Improving Access’ award in 2008, and the Health Service Journal’s innovation award in 2008. He won ‘New network of the Year’ at the NHS Confederation awards in 2008 for establishing the Greater Manchester pathology network  
  • Over 2006/2007 he was appointed programme lead for UK’s 50,000 healthcare scientists, part of the Department of Health team harmonising the foundations for education and training of life scientists, physiological scientists, medical physicists and clinical engineers under the Modernising Scientific Careers programme, now established as the sole career pathway for all NHS scientists. He led the scoping work to establish prescribing roles for healthcare scientists, and established criteria for the conduct of Point of Care Testing for the NHS Health Checks programme.
  • He was appointed consultant biochemist (2008) and clinical lead (2010) for laboratory medicine at Bolton NHS Foundation Trust where he also heads the ante-natal screening services for chromosomal abnormalities for northwest England, the north Midlands and Scotland. Since 2009 he has established the largest quality assurance scheme in UK for ‘high street’ cholesterol and HbA1c testing.
  • He became chair of EC4’s Foundation Board in 2011 from where he led the revision of version 4 of the education and training syllabus for Specialists in Laboratory Medicine. He oversaw the final integration of EC4 into EFLM in 2016 and is currently chair of EFLM’s Profession Committee with an overarching remit to achieve a Common Training Framework that recognises Specialists in Laboratory Medicine under the EU Commission’s 2013/55/EC Directive (the Recognition of Professional Qualifications).

His talk will provide an update on the content and expectations described in version 5 of the EFLM syllabus, progress at EU Commission level in presenting a Common Training Framework that identifies specialist practice in laboratory medicine, and the new ways of working for the Register of European Specialists in Laboratory Medicine (EUSpLM).  


Michael Neumeier



Univ.-Prof. Dr. med. Michael Neumaier

Medical Faculty Mannheim of the University Heidelberg, University Medicine Mannheim, Institute for Clinical Chemistry, MANNHEIM, Germany

 

 

Professor Michael Neumaier has graduated in 1985 from Medical School University of Bonn, Germany. Between 1986 and 1988 he was a research fellow due to a grant by German Research Council at the City of Hope National Cancer Centre in Duarte, CA, where he was educated in fields of molecular cloning of members of the Carcinoembryonic Antigen (CEA) family and cloning and genetic engineering of monoclonal antibodies. Between 1988 and 1991 his medical residencies were in Clinical Chemistry and Laboratory Medicine at the University of Aachen, Germany. In 1992 he was approved as a Clinical Chemist by the German Society for Clinical Chemistry (DGKC), while between 1991 and 1998 his residencies were at the University Hospital Eppendorf, University of Hamburg, Germany. In 1996 he was appointed Associate Professor at University Hamburg. In 1998, he became a Physician specialist in Laboratory Medicine by approval of the German Medical Council. In 2002 he was promoted to a university professor, he became Chair for Clinical Chemistry at the Medical Faculty Mannheim Heidelberg University, Director of the Institute for Clinical Chemistry and Head of the Central Laboratories of the Mannheim University of Medicine (UMM). Since 2007 he was appointed a guest professor at Zagreb University School of Medicine.

From 2012 to 2015 he was a member of the Executive Board of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). Between 2014 and 2015 he served as President of DGLK, chair of the foundation “Pathobiochemistry and Molecular Diagnostics” (DGKL) and member of the Board of the Reference Institute for Bioanalytics (RfB, Bonn, Germany). From 2013 to 2015 he was a member of Executive Board and Dean of studies at Mannheim Medical Faculty, University of Heidelberg. Since 2015, he is vice dean at the same faculty. Since 2017 he serves his 2-year mandate as vice–president (president elect) of the European Federation for Clinical Chemistry and Laboratory Medicine (EFLM), while in next mandate (2018-2019) he will serve as President.

AWARDS
*1993 Werner-Otto-Foundation for the Advancement of Medicine
*1994 Gabor-Szasz Award of the German Society for Clinical Chemistry (DGKC)
*1998 Konietzny Award of the Cancer Society Hamburg
*2007 appointed Guest Professor of the University of Zagreb, Croatia
*2011 Abbott Award of the International Society for Clinical Chemistry and Laboratory Medicine (IFCC) on the occasion of the IFCC World Lab Congress in Berlin, Germany

Professor Neumaier is an active member of numerous scientific and professional societies and working-groups: German Society for Clinical Chemistry and Laboratory Medicine (DGKL), Scientific Advisory Board of the „Reference Institute for Bioanalytics of the DGKL“ (RfB), Director of the national “External Quality Assessment in Laboratory Medicine” program (80 EQA schemes) by appointment of the German Medical Council (BÄK), Advisory Board of the BÄK and chairman of the Expert Panel group on Molecular Diagnostics (D5) of the BÄK, Founding member of the National Gene Diagnostics Commission advising the German Federal Government at the Robert-Koch-Institute, Berlin; organizer of 5 External Quality Assessment programs in Molecular Genetic Testing and Molecular Methodology (DNA isolation, Genotyping, DNA Sequencing, Plasma-DNA) with up to 700 participating laboratories in 29 countries including Europe, Australia and Taiwan.

He was a founding member, past chairman and current member of the DGKL-Working Groups “Molecular and Chip Diagnostics“, “Bioinformatics“ and “Biobanking“ between 1998 and 2013. From 2000 to 2014 he was organizer of the DGKL “Tutzing Conferences on Molecular Biology” (Starnberg Lake, Bavaria). He was also a founder and chair of the Section “Molecular Diagnostics” of the DGKL between 2009 and 2013 and a founding member and Past Chairman of the Committee for Clinical Molecular Biology Curriculum (C-MBC/EMD) of the Education and Management Division of the International Federation for Clinical Chemistry (IFCC) between 2004 and 2014. In 2015 he became a member of the Committee for Cancer Genomics (C-CG) of IFCC-SD and member of the IFCC Task Force on Pharmacogenomics of IFCC-SD.

 His research interests include mechanisms of early colorectal tumorigenesis, structure/function of variable immune receptors expressed by myeloid cells, molecular diagnostics of cancer recurrence in cfDNA in plasma, protease profiling of tumours and their metastases and preanalytical aspects in biomolecular quality of clinical and research specimens in biomaterial archives.

HR EN